drugset / Trial / NCT05839574

Letrozole add-on in the Treatment of Cesarean Scar Pregnancy

NCT05839574

Completed 28 enrolled Jagiellonian University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

It is hypothesized that the inhibition of estradiol production by letrozole may interfere with physiological effects of progesterone necessary to maintain the pregnancy. There is no reference treatment of cesarean scar pregnancy (CSP) as the limited number of cases precludes the extrapolation of results. In our center we successfully use two-step treatment with methotrexate (MTX) followed by hysteroscopic removal of products of conception (POC). The time in between is needed to achieve a decrease in the trophoblast's vital potential (B-hCG fall) and its vascularization. Additional administration of letrozole could further reduce the vital potential of the pregnancy, eliminating the need for another dose of MTX, resulting in faster healing and lower rate of complications.

Timeline

Start
2021-01-01
Primary completion
2022-12-30
Completion
2023-10-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Letrozole Other / unclassified 5 mg Oral
Comparator MTX Unknown 50 mg Intravenous
Comparator MTX Unknown 100 mg Intravenous
Comparator Potassium Chloride Small molecule 30 mg

Indications